Needham Gives a Buy Rating to Apellis Pharmaceuticals (APLS)

In a report released today, Joseph Stringer from Needham assigned a Buy rating to Apellis Pharmaceuticals (APLSResearch Report), with a price target of $65.00. The company’s shares closed last Monday at $52.73.

According to, Stringer ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.8% and a 24.1% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.

Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $74.20, a 51.4% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $62.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $58.47 and a one-year low of $25.49. Currently, Apellis Pharmaceuticals has an average volume of 642.7K.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.